154 related articles for article (PubMed ID: 16928818)
1. Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer.
Akbulut H; Tang Y; Akbulut KG; Maynard J; Zhang L; Deisseroth A
Mol Cancer Ther; 2006 Aug; 5(8):1975-85. PubMed ID: 16928818
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy targeted to cancer tissue potentiates antigen-specific immune response induced by vaccine for in vivo antigen loading and activation of dendritic cells.
Akbulut H; Tang Y; Akbulut KG; Maynard J; Deisseroth A
Mol Ther; 2008 Oct; 16(10):1753-60. PubMed ID: 18728641
[TBL] [Abstract][Full Text] [Related]
3. Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens.
Tang Y; Zhang L; Yuan J; Akbulut H; Maynard J; Linton PJ; Deisseroth A
Blood; 2004 Nov; 104(9):2704-13. PubMed ID: 15238426
[TBL] [Abstract][Full Text] [Related]
4. Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells.
Akbulut H; Tang Y; Akbulut KG; Maynard J; Deisseroth A
Gene Ther; 2010 Nov; 17(11):1333-40. PubMed ID: 20596057
[TBL] [Abstract][Full Text] [Related]
5. Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer.
Tang Y; Akbulut H; Maynard J; Petersen L; Fang X; Zhang WW; Xia X; Koziol J; Linton PJ; Deisseroth A
J Immunol; 2006 Oct; 177(8):5697-707. PubMed ID: 17015759
[TBL] [Abstract][Full Text] [Related]
6. TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases.
Deisseroth A; Tang Y; Zhang L; Akbulut H; Habib N
Cancer Gene Ther; 2013 Feb; 20(2):65-9. PubMed ID: 23238593
[TBL] [Abstract][Full Text] [Related]
7. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells.
Zhang L; Tang Y; Akbulut H; Zelterman D; Linton PJ; Deisseroth AB
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15101-6. PubMed ID: 14645711
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
9. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination.
Wan Y; Bramson J; Carter R; Graham F; Gauldie J
Hum Gene Ther; 1997 Jul; 8(11):1355-63. PubMed ID: 9295130
[TBL] [Abstract][Full Text] [Related]
11. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
[TBL] [Abstract][Full Text] [Related]
12. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.
Chen Y; Emtage P; Zhu Q; Foley R; Muller W; Hitt M; Gauldie J; Wan Y
Gene Ther; 2001 Feb; 8(4):316-23. PubMed ID: 11313806
[TBL] [Abstract][Full Text] [Related]
13. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
Liu Y; Xia D; Li F; Zheng C; Xiang J
Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
18. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
Bernt KM; Ni S; Tieu AT; Lieber A
Cancer Res; 2005 May; 65(10):4343-52. PubMed ID: 15899826
[TBL] [Abstract][Full Text] [Related]
19. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
